Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors

NCT04503278 is registered in ClinicalTrials.gov with BioNTech Cell & Gene Therapies GmbH as lead sponsor.

NCT NCT04503278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04503278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors
Lead sponsor
BioNTech Cell & Gene Therapies GmbH
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 16, 2020
Completion date
August 31, 2041
Enrollment
214 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor